Real-World Experience Using Topical Therapy—Calcipotriol and Betamethasone Dipropionate Foam in Adults with Beyond-Mild Psoriasis
| Autor: | Diane Chayer, Tobias Anger, A. Martorell, R. Aschoff, Anthony Bewley |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Betamethasone dipropionate Dermatology Systemic therapy 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Psoriasis medicine Effective treatment In patient Calcipotriol Original Research business.industry medicine.disease humanities Calcipotriol/betamethasone dipropionate aerosol foam Real-world experience Topical medication stomatognathic diseases chemistry 030220 oncology & carcinogenesis Oral and maxillofacial surgery Topical therapy lipids (amino acids peptides and proteins) business medicine.drug |
| Zdroj: | Dermatology and Therapy |
| ISSN: | 2190-9172 2193-8210 |
| DOI: | 10.1007/s13555-021-00501-3 |
| Popis: | Introduction Determining optimal treatment for moderate plaque psoriasis can be challenging. Recent studies have demonstrated the effectiveness of calcipotriol and betamethasone dipropionate (Cal/BD) foam in patients with moderate-to-severe plaque psoriasis. Methods This research explored the use of Cal/BD foam in patients with beyond-mild psoriasis (defined as patients eligible for topical treatment, systemic treatment, or combined topical/systemic treatments) using an online questionnaire, retrospective medical-record review, and by capturing the attitudes and treatment approaches of dermatology specialists. Results Data from 409 patients with beyond-mild psoriasis treated with Cal/BD foam were provided by 120 dermatology specialists from Germany, Spain, and the UK. Cal/BD foam was prescribed as monotherapy for most (58%) patients and was considered to be effective. Cal/BD foam was infrequently used in combination with biologics (7%) in this segment; 26% of patients received Cal/BD foam in combination with a non-biologic systemic treatment. Cal/BD foam prescribers generally use topical agents to bridge the waiting time to non-biologic/biologic systemic treatment, and as an add-on to systemic treatment for residual lesions. Conclusions In patients with beyond-mild psoriasis, the most commonly prescribed topical medication was Cal/BD foam, which was regarded as an effective treatment. Further research is needed to determine optimal use of Cal/BD foam in these patients. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-021-00501-3. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|